Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1b/2 study of mosunetuzumab with polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma
MOH_2018-11-06_004734Phase 2Not yet recruiting
- Sponsor
- Roche
- Start
- Nov 2018
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of mosunetuzumab and polatuzumab vedotin in mature B-cell lymphoma, follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL) (9 arms), sponsored by Roche. Primary endpoints: Safety, Tolerability and 2 more. Planned start Nov 2018; status: not yet recruiting.
02
Drugs
mosunetuzumabpolatuzumab vedotin
03
Conditions
mature B-cell lymphomafollicular lymphoma (FL)diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on MOH_2018-11-06_004734.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2018-11-06_004734.